



## **Manhattan Pharmaceuticals' Alan G. Harris, M.D., Ph.D. to Chair Metabolic Syndrome Conference**

NEW YORK, NY SEPT 19, 2006 -- Manhattan Pharmaceuticals, Inc. (Amex: MHA) today announced that Alan G. Harris, MD, PhD, the company's Chief Medical Officer, will chair the upcoming two-day Metabolic Syndrome Conference: Achieving Successful Drug Approval While Seizing Untapped Commercial Opportunities. The event will be held September 26-27 at the Radisson Hotel Boston in Boston, MA.

In addition to his leadership responsibilities at the conference, Dr. Harris will participate as a panelist in the closing session titled: "Opportunities and Challenges for Future Treatments of the Metabolic Syndrome," which will be held Wednesday, September 27 at 3:45pm EDT.

Other expert speakers to be featured at the conference include: Douglas Greene, MD, Chief Medical Officer, sanofi-aventis; Rebecca Taub, MD, VP Research-Metabolic Diseases, Hoffman La-Roche; Tu Nguyen, MD, Director-Cardiovascular, Metabolic & Endocrine Diseases, Pfizer Global Research & Development; Pierre Rosensweig, MD, VP-Internal Medicine Clinical Development, sanofi-aventis; Karsten Wassermann, PhD, DSc, Project VP-Clinical Development, Medical & Regulatory Affairs, Novo Nordisk; and David V. Erbe, PhD, Cardiovascular & Metabolic Diseases, Wyeth Research.

To learn more about the conference, or to request a brochure, please go to <http://www.marcusevans.com/events/CFEventinfo.asp?EventID=10903> or visit the Manhattan Pharmaceuticals, Inc. website at <http://www.manhattanpharma.com>.

### **About Manhattan Pharmaceuticals, Inc.**

Manhattan Pharmaceuticals, Inc., a development-stage pharmaceutical company, acquires and develops proprietary prescription drugs for large, underserved patient populations. In view of the worldwide obesity epidemic, the company is developing OE, an orally administered novel therapeutic for the treatment of obesity. To meet the needs of other major, underserved medical markets while lowering development risks, Manhattan Pharmaceuticals is also developing PTH (1-34), a peptide believed to be a regulator of epidermal cell growth, for psoriasis, and Propofol Lingual Spray, a convenient, proprietary lingual spray formulation of propofol, the world's best-selling general anesthetic, as a sedative-hypnotic for use during diagnostic and therapeutic procedures. (<http://www.manhattanpharma.com>)